Fullife Healthcare Secures Rs 300 Crore in Series D Funding

Fullife Healthcare, a leading name in consumer health and wellness, has successfully raised Rs 300 crore (approximately $32 million) in a Series D funding round, spearheaded by Elev8 Venture Partners, with contributions from its limited partners. This funding signifies Elev8’s inaugural venture into the direct-to-consumer (D2C) sector.

The newly acquired funds will be strategically used to propel growth across Fullife’s diverse brands and facilitate entry into new segments, including digestive health, sleep support, and protein-oriented nutrition.

Brand Portfolio and Offerings

Fullife’s brand Fast&Up focuses on active nutrition, providing essential products like protein supplements, workout aids, and immunity boosters. Chicnutrix, another initiative by Fullife launched in 2019, is dedicated to women’s wellness, offering solutions for skincare, haircare, PCOS, UTI care, and other health-related concerns. Last fiscal year, the sales from these offerings constituted the company’s primary source of revenue.

The company also operates NightOut, enhancing its portfolio that currently features over 100 SKUs across various categories, including hydration, metabolic health, sports nutrition, and beauty wellness.

Growth Strategies

Fullife is committed to enhancing its distribution network and expanding its retail presence, aiming to improve consumer access via online and digital channels. This strategy is designed to boost market penetration across India.

Investment in scaling manufacturing, creating innovative product formats, and enhancing the consumer experience is also a priority for the company.

International Expansion Plans

Currently, Fullife’s products are available in over 40 countries through its prominent brands. The company is setting its sights on further international expansion, particularly in markets such as the UK, GCC, and the US, by strengthening its distribution and amplifying brand visibility.

To date, Fullife Healthcare has raised more than $72 million, which includes $22 million from Morgan Stanley in 2021. In FY25, the company reported a 36.4% year-on-year increase in operating revenue, reaching Rs 256.04 crore, up from Rs 187.64 crore in FY24. Additionally, losses have been reduced significantly, falling to Rs 13.42 crore from Rs 30.16 crore during the same timeframe.